Tucatinib's journey from clinical development to clinical practice : New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
Copyright © 2023 Elsevier Ltd. All rights reserved..
Approximately 20% of breast cancers (BCs) overexpress human epidermal growth factor receptor 2 (HER2), a transmembrane glycoprotein with tyrosine kinase activity, encoded by ERBB2 gene. Historically, HER2 overexpression has been linked with increased disease recurrence and a worse prognosis. However, the increasing availability of different anti-HER2 compounds and combinations is progressively improving HER2-positive BC outcome, thus requiring expertise to prioritize both overall survival (OS) prolongation and quality of life, without neglecting the accessibility to further treatment lines with a low attrition rate. In this context, tucatinib, an oral tyrosine kinase inhibitor, has recently been granted approval by regulatory agencies based on evidence from the HER2CLIMB, a clinical trial which randomized patients with metastatic BC to receive trastuzumab and capecitabine with either tucatinib or placebo. A distinctive feature of this study was the inclusion of patients with new or active brain metastases (BMs) at study entry, a population traditionally excluded from clinical trials. Thus, HER2CLIMB provides the first solid evidence of an OS benefit in patients with BC and BMs, addressing a long standing unmet medical need, especially given the high incidence of central nervous system metastatic spread in patients with HER2-positive disease. This review provides an overview of the molecular and clinical landscape of tucatinib for the treatment of advanced BC. It focuses on the technological journey that drove the development of this therapeutic innovation, from preclinical data to clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Cancer treatment reviews - 120(2023) vom: 02. Nov., Seite 102618 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Criscitiello, Carmen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
234248D0HH |
|---|
| Anmerkungen: |
Date Completed 13.10.2023 Date Revised 18.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ctrv.2023.102618 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361378556 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361378556 | ||
| 003 | DE-627 | ||
| 005 | 20231226085018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2023.102618 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361378556 | ||
| 035 | |a (NLM)37639757 | ||
| 035 | |a (PII)S0305-7372(23)00111-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Criscitiello, Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tucatinib's journey from clinical development to clinical practice |b New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2023 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Approximately 20% of breast cancers (BCs) overexpress human epidermal growth factor receptor 2 (HER2), a transmembrane glycoprotein with tyrosine kinase activity, encoded by ERBB2 gene. Historically, HER2 overexpression has been linked with increased disease recurrence and a worse prognosis. However, the increasing availability of different anti-HER2 compounds and combinations is progressively improving HER2-positive BC outcome, thus requiring expertise to prioritize both overall survival (OS) prolongation and quality of life, without neglecting the accessibility to further treatment lines with a low attrition rate. In this context, tucatinib, an oral tyrosine kinase inhibitor, has recently been granted approval by regulatory agencies based on evidence from the HER2CLIMB, a clinical trial which randomized patients with metastatic BC to receive trastuzumab and capecitabine with either tucatinib or placebo. A distinctive feature of this study was the inclusion of patients with new or active brain metastases (BMs) at study entry, a population traditionally excluded from clinical trials. Thus, HER2CLIMB provides the first solid evidence of an OS benefit in patients with BC and BMs, addressing a long standing unmet medical need, especially given the high incidence of central nervous system metastatic spread in patients with HER2-positive disease. This review provides an overview of the molecular and clinical landscape of tucatinib for the treatment of advanced BC. It focuses on the technological journey that drove the development of this therapeutic innovation, from preclinical data to clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Brain metastasis | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a Innovation | |
| 650 | 4 | |a TKI | |
| 650 | 4 | |a Tucatinib | |
| 650 | 7 | |a tucatinib |2 NLM | |
| 650 | 7 | |a 234248D0HH |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Corti, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a De Laurentiis, Michelino |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchini, Giampaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pistilli, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Cinieri, Saverio |e verfasserin |4 aut | |
| 700 | 1 | |a Castellan, Lucio |e verfasserin |4 aut | |
| 700 | 1 | |a Arpino, Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Conte, Pierfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Di Meco, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Guarneri, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Visani, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Livi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Puglisi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a De Placido, Sabino |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment reviews |d 1993 |g 120(2023) vom: 02. Nov., Seite 102618 |w (DE-627)NLM000409189 |x 1532-1967 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2023 |g day:02 |g month:11 |g pages:102618 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctrv.2023.102618 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2023 |b 02 |c 11 |h 102618 | ||